ISO 9001:2015   |   ISO 27001:2013

MMS Holdings Inc. Funds $1 Million Zika Vaccine Development Award

Posted on 3/14/2016 6:00 AM

Canton, MI — MMS Holdings Inc. a specialty data-focused CRO headquartered in Canton, MI has announced a $1M award toward the development of a Zika vaccine. The award is being offered as data services to qualified pharmaceutical companies supporting the commercial development of a vaccine for approval in the United States and/or other global regulatory markets.

MMS CSO, Dr. Uma Sharma said “Our experience with clinical data, especially in the area of vaccines, puts MMS in a strong position to support this vital community need. We all need to do our part to combat emerging threats to global health and to support drug development in these areas. We hope that this award will eliminate the financial roadblocks some companies may face when pursuing BLAs in this area.”

The Zika virus disease (Zika) is a disease spread to people primarily through the bite of an infected Aedes species mosquito. Patients most commonly report fever, rash, joint pain, and conjunctivitis (red eyes). Since these are mostly mild and patients recover within a few days, they rarely seek medical treatment and the infection goes unnoticed. In pregnant women however, Zika can spread from the mother to the fetus and cause birth defects, most notably microencaphaly. In addition, a serious neurological disorder Guillain-barre syndrome (GBS) has been reported in patients affected by the Zika virus.

On Feb 1, 2016, the World Health Organization (WHO) declared Zika virus a public health emergency of international concern (PHEIC). Though originally reported in Brazil, the Zika virus will likely continue to spread to new areas.

All applications for the MMS Holdings Inc. Zika Vaccine Award will be reviewed by the MMS scientific board comprised of experts in the field of new drug approvals led by Dr. Bob Rappaport, Dr. Ethan Weiner, Dr. Atul Pande, and Dr. Ed Harrigan.

Applications will be accepted through December 19, 2016. Companies are encouraged to contact MMS’ lead Alan Nicolle at to obtain application forms.

About MMS Holdings Inc.

MMS Holdings Inc. ( is a global clinical research organization (CRO) that focuses on regulatory submission support for the pharmaceutical, biotech and medical device industries. Our strong industry experience and scientific approach to drug development makes us a valuable partner in creating compelling submissions that meet rigorous regulatory standards. Our clients span from top 10 pharma to virtual biotechs, and we support each one with the same standard of excellence. MMS’ core service areas include medical and regulatory writing, biostatistics, clinical programming, data management, clinical development, clinical trial disclosure, regulatory affairs, regulatory submissions and pharmacovigilance. Our mission is to deliver high-quality services, rooted in good science and decades of regulatory experience, that will assist our clients in developing and marketing life-changing therapies, thereby positively affecting patients’ lives worldwide.

Regulatory Submission Support Based on Strong Science and Strength of Process. The difference is in the data!